Aileron Therapeutics Q2 2024 GAAP EPS $(0.45) Misses $(0.42) Estimate; Cash Position $21.9M
Portfolio Pulse from Benzinga Newsdesk
Aileron Therapeutics (NASDAQ:ALRN) reported a Q2 2024 GAAP EPS of $(0.45), missing the analyst estimate of $(0.42) by 7.14%. This represents a 15.38% increase in losses compared to the same period last year. The company's cash position stands at $21.9M.
August 15, 2024 | 7:07 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aileron Therapeutics reported a Q2 2024 GAAP EPS of $(0.45), missing the analyst estimate of $(0.42) by 7.14%. This represents a 15.38% increase in losses compared to the same period last year. The company's cash position stands at $21.9M.
The reported EPS miss and increased losses compared to the previous year are likely to negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100